Camrelizumab trials for Breast cancer

All Camrelizumab trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Camrelizumab for Breast cancer

• A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
  NCT04481763 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
  NCT05760378 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
  NCT05761470 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
  NCT06516289 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT06121557 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
  NCT05981001 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
  NCT05447702 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location

Common questions

How many trials study Camrelizumab for Breast cancer?

8 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.